FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES FIRST QUARTER 2017 RESULTS

Research Triangle Park, NC, May 12, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the first quarter ended March 31, 2017. Upcoming Events for […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2016 FINANCIAL RESULTS

Research Triangle Park, NC, March 30, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for  the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2016. “We are pleased with […]

FENNEC ANNOUNCES THE LANCET ONCOLOGY PUBLICATION OF CHILDREN’S ONCOLOGY GROUP STUDY OF SODIUM THIOSULFATE

Research Triangle Park, NC, December 1, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced The Lancet Oncology published the results from the Children’s Oncology Group, “Effects of Sodium Thiosulfate versus Observation […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2016 RESULTS

SIOPEL 6 Updated Interim Results Presented at the International Society of Pediatric Oncology (SIOP) -confirms no evidence of tumor protection and final audiometry results will be available in the fourth quarter of 2017 Research Triangle Park, NC, November 14, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the […]

FENNEC ANNOUNCES UPDATE OF SIOPEL 6 STUDY ON SODIUM THIOSULFATE (STS) PRESENTED AT THE INTERNATIONAL SOCIETY OF PAEDIATRIC ONCOLOGY (SIOP) 2016 MEETING

No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin alone vs cisplatin + STS with no evidence of tumor protection  Final audiometry results will be available at the end of 2017 Research Triangle Park, NC, October 24, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty […]

FENNEC TO PRESENT AT RODMAN & RENSHAW 18TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN NEW YORK ON SEPTEMBER 13, 2016

Research Triangle Park, NC, September 8, 2016 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The Company will be presenting at 3:25 EDT on Tuesday, September 13, 2016. […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES SECOND QUARTER 2016 RESULTS

SIOPEL 6 interim results presented in oral presentation at ASCO 2016 confirms no evidence of tumor protection and is consistent with previous updates. Initial hearing efficacy data are “encouraging” with final hearing results expected in H2 2017. Closing of $5.0 million financing by Essetifin SpA (formerly Sigma Tau Finanziaria SpA) provides sufficient reserves to complete […]

FENNEC ANNOUNCES APPOINTMENT OF MARCO BRUGHERA TO THE BOARD OF DIRECTORS

Research Triangle Park, NC, August 11, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the appointment of Marco Brughera, DVM, CEO and Global Head of Sigma Tau Rare Disease, to its […]

FENNEC TO PRESENT AT CANTOR FITZGERALD’s 2nd ANNUAL HEALTHCARE CONFERENCE IN NEW YORK ON JULY 13, 2016

Research Triangle Park, NC, July 6, 2016 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July 13, 2016. The conference is being held at the Le Parker Meridian in New […]

Fennec Announces Results of Annual Meeting

Research Triangle Park, NC — (Marketwired) – June 8, 2016– Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 9, 2016 (the “Circular”) for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in […]

FENNEC ANNOUNCES INTERIM RESULTS OF SIOPEL 6 STUDY ON SODIUM THIOSULFATE (STS) PRESENTED AT THE AMERICAN ASSOCIATION OF CLINICAL ONCOLOGY (ASCO) 2016 MEETING

No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin vs cisplatin + STS with no evidence of tumor protection  The interim results of the first 68 patients achieving centrally reviewed pure tone audiometry at or above 3.5 years of age were encouraging Research Triangle Park, NC, June 6, […]

FENNEC ANNOUNCES UPCOMING EVENTS AND PRESENTATIONS

Research Triangle Park, NC, May 18, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today upcoming events and presentations: ASCO 2016 – STS will be featured in […]

FENNEC ANNOUNCES SECOND CLOSING OF PRIVATE PLACEMENT

Research Triangle Park, NC, May 16, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed the second closing of the previously announced non-brokered […]

FENNEC ANNOUNCES SODIUM THIOSULFATE PRESENTATION FOR PREVENTION OF OTOTOXICITY IN CHILDREN AT ASCO MEETING

SIOPEL 6 oral presentation for hearing protection in standard risk hepatoblastoma on June 5 at ASCO 2016 Research Triangle Park, NC, April 20, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity […]

FENNEC ANNOUNCES $5.0 MILLION PRIVATE PLACEMENT OF COMMON SHARES BY SIGMA TAU FINANZIARIA

Research Triangle Park, NC, April 8, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it intends to complete a non-brokered private placement (the “Offering”) of […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2015 FINANCIAL RESULTS

Research Triangle Park, NC, March 28, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for  the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2015. “Throughout 2015 we continued […]

FENNEC ANNOUNCES NEW CHAIRMAN OF THE BOARD

Research Triangle Park, NC, December 9, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for  the prevention of platinum-induced ototoxicity in pediatric patients, announced the appointment of Khalid Islam, PhD, as Chairman of the Board of Directors of Fennec. Dr. Islam has […]